Loading stock data…
BDX
$149.31+0.27 (+0.18%)
Market ClosedLast close May 1
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Becton, Dickinson and Company in the Healthcare sector is trading at $149.31. The stock is currently 20% below its 52-week high of $187.35, remaining 2.4% below its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why BDX maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$149.31
Potential Downside
23.8%
Whystock Fair Value$113.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$191.46+28.2%
Range$157.00 – $225.00
Fundamentals
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$56.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.43
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Strong income play. Yield provides a meaningful total return floor.
270.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.95%
Volume
Today's trading volume
1.82M
Recent News
Earnings Preview: Becton Dickinson (BDX) Q2 Earnings Expected to Decline
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is It Time To Reconsider Becton Dickinson (BDX) After Its Recent Share Price Weakness?
With Becton Dickinson trading at US$149.52, you might be wondering whether the current price reflects a fair deal or if the market is mispricing this healthcare heavyweight. Over the short term, the stock has seen a 4.6% decline over 7 days and a 3.2% decline over 30 days, while returns sit at a 23.3% decline year to date, a 5.7% decline over 1 year, a 23.7% decline over 3 years, and a 15.6% decline over 5 years. Recent news flow around Becton Dickinson has focused on its role as a large...
Strength Seen in Lifevantage (LFVN): Can Its 8.5% Jump Turn into More Strength?
Lifevantage (LFVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Assessing Becton Dickinson’s Valuation After Recent Share Weakness And Planned Business Separation
Recent share performance and business snapshot Becton Dickinson (BDX) has drawn investor attention after a challenging stretch for the share price, with negative returns over the past month, past 3 months, year to date and past 3 years. The company operates across Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. It generates US$21.9b in revenue and US$1.8b in net income, and serves healthcare institutions, laboratories and the pharmaceutical industry...
Piper Sandler Trims Becton Dickinson (BDX) PT on Model Revisions
Becton, Dickinson and Company (NYSE:BDX) is included among the 10 Best Dividend Aristocrat Stocks to Buy in 2026. On April 17, Jason Bednar at Piper Sandler lowered the price target on Becton, Dickinson and Company (NYSE:BDX) to $159 from $170 and kept a Neutral rating. The firm adjusted parts of its Q2 revenue growth assumptions […]